AU2171501A - Improvements relating to double-stranded rna inhibition - Google Patents

Improvements relating to double-stranded rna inhibition

Info

Publication number
AU2171501A
AU2171501A AU21715/01A AU2171501A AU2171501A AU 2171501 A AU2171501 A AU 2171501A AU 21715/01 A AU21715/01 A AU 21715/01A AU 2171501 A AU2171501 A AU 2171501A AU 2171501 A AU2171501 A AU 2171501A
Authority
AU
Australia
Prior art keywords
double
stranded rna
improvements relating
rna inhibition
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21715/01A
Inventor
Thierry Bogaert
Ann Lissens
Katherine Mortier
Geert Plaetinck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Devgen NV
Original Assignee
Devgen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Devgen NV filed Critical Devgen NV
Publication of AU2171501A publication Critical patent/AU2171501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU21715/01A 1999-12-24 2000-12-22 Improvements relating to double-stranded rna inhibition Abandoned AU2171501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930691.2A GB9930691D0 (en) 1999-12-24 1999-12-24 Improvements relating to double-stranded RNA inhibition
GB9930691 1999-12-24
PCT/EP2000/013149 WO2001048183A2 (en) 1999-12-24 2000-12-22 Improvements relating to double-stranded rna inhibition

Publications (1)

Publication Number Publication Date
AU2171501A true AU2171501A (en) 2001-07-09

Family

ID=10867073

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21715/01A Abandoned AU2171501A (en) 1999-12-24 2000-12-22 Improvements relating to double-stranded rna inhibition

Country Status (3)

Country Link
AU (1) AU2171501A (en)
GB (1) GB9930691D0 (en)
WO (1) WO2001048183A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
ES2374290T3 (en) 1998-03-20 2012-02-15 Commonwealth Scientific And Industrial Research Organisation SYNTHETIC GENES AND GENETIC CONSTRUCTS THAT INCLUDE THE SAME.
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (en) 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
DE10163098B4 (en) 2001-10-12 2005-06-02 Alnylam Europe Ag Method for inhibiting the replication of viruses
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10202419A1 (en) 2002-01-22 2003-08-07 Ribopharma Ag Method of inhibiting expression of a target gene resulting from chromosome aberration
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003290597A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
JP4579911B2 (en) 2003-06-03 2010-11-10 アイシス・ファーマシューティカルズ・インコーポレイテッド Regulation of survivin expression
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
AU2005244258B2 (en) 2004-04-09 2010-07-01 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
CA2584960A1 (en) 2004-10-21 2006-05-04 Charles L. Niblett Methods and materials for conferring resistance to pests and pathogens of plants
EP2426208B1 (en) 2005-09-16 2016-11-09 Monsanto Technology, LLC Methods for genetic control of insect infestations in plants and compositions thereof
CN105388294B (en) * 2014-08-01 2017-01-25 上海交通大学医学院附属瑞金医院 Application of mitochondria trifunctional enzyme alpha subunit in preparation of drug target for inhibiting lipid accumulation of AA005

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
GB9908677D0 (en) * 1999-04-15 1999-06-09 Devgen Nv Compound assay

Also Published As

Publication number Publication date
GB9930691D0 (en) 2000-02-16
WO2001048183A3 (en) 2001-12-06
WO2001048183A2 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
AU2171501A (en) Improvements relating to double-stranded rna inhibition
AU2001279134A1 (en) Nucleotide incorporating enzymes
AU2001238030A1 (en) Detection of single nucleotide polymorphisms
AU2002245184A1 (en) Nucleic acid amplification
AU6172600A (en) Improvements relating to security
AU2002220553A1 (en) Bioreactor
AU2001280167A1 (en) Novel propenohydroxamic acid derivatives
AU2001237992A1 (en) Purification of oligonucleotides
AUPQ008799A0 (en) Genome sequencing
AU2001245489A1 (en) Human single nucleotide polymorphisms
AU7737300A (en) Dna-cleaving rnase p rna
AUPQ262599A0 (en) Gene expression
AU1070501A (en) Quantitation of rna transcripts using genomic dna as the internal amplification competitor
AU2001264247A1 (en) GASC1 gene
AU2376200A (en) Insulin-synthesis genes
AU2001293874A1 (en) System to prevent snoring
AU6859500A (en) Plant gene
AU6488800A (en) Dna sequences specific to rice centromeres
AU1585201A (en) Approaches to identify genetic traits
AU7461900A (en) Nucleotide sequences
AU6871900A (en) Tsg-like gene
AU1870000A (en) Gene therapy-2
AU6006100A (en) Plant genes
AU6382000A (en) Genome analysis
AU2001233847A1 (en) Interferon-alpha induced genes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase